These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 37401056)

  • 1. Denosumab use in osteogenesis imperfecta: an update on therapeutic approaches.
    Majdoub F; Ferjani HL; Nessib DB; Kaffel D; Maatallah K; Hamdi W
    Ann Pediatr Endocrinol Metab; 2023 Jun; 28(2):98-106. PubMed ID: 37401056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized treatment with denosumab in children with osteogenesis imperfecta - follow up of a trial cohort.
    Hoyer-Kuhn H; Rehberg M; Netzer C; Schoenau E; Semler O
    Orphanet J Rare Dis; 2019 Sep; 14(1):219. PubMed ID: 31533771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two years' experience with denosumab for children with osteogenesis imperfecta type VI.
    Hoyer-Kuhn H; Netzer C; Koerber F; Schoenau E; Semler O
    Orphanet J Rare Dis; 2014 Sep; 9():145. PubMed ID: 25257953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Denosumab for Osteoporosis in Three Female Patients with Osteogenesis Imperfecta.
    Uehara M; Nakamura Y; Takahashi J; Kamimura M; Ikegami S; Suzuki T; Uchiyama S; Yamaguchi T; Kosho T; Kato H
    Tohoku J Exp Med; 2017 Jun; 242(2):115-120. PubMed ID: 28626166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI.
    Semler O; Netzer C; Hoyer-Kuhn H; Becker J; Eysel P; Schoenau E
    J Musculoskelet Neuronal Interact; 2012 Sep; 12(3):183-8. PubMed ID: 22947550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab: an Emerging Therapy in Pediatric Bone Disorders.
    Boyce AM
    Curr Osteoporos Rep; 2017 Aug; 15(4):283-292. PubMed ID: 28643220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI.
    Trejo P; Rauch F; Ward L
    J Musculoskelet Neuronal Interact; 2018 Mar; 18(1):76-80. PubMed ID: 29504582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitigating the Denosumab-Induced Rebound Phenomenon with Alternating Short- and Long-Acting Anti-resorptive Therapy in a Young Boy with Severe OI Type VI.
    Seale E; Molina MO; Carsen S; Sheffield H; Koujok K; Robinson ME; Feber J; Smit K; Page M; Walker S; Khan N; Konji VN; Rauch F; Ward LM
    Calcif Tissue Int; 2023 May; 112(5):613-620. PubMed ID: 36867194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Denosumab Therapy for Osteogenesis Imperfecta Patients with Osteoporosis-Case Series.
    Kobayashi T; Nakamura Y; Suzuki T; Yamaguchi T; Takeda R; Takagi M; Hasegawa T; Kosho T; Kato H
    J Clin Med; 2018 Nov; 7(12):. PubMed ID: 30477250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab in pediatric bone disorders and the role of RANKL blockade: a narrative review.
    Wang D; Tang X; Shi Q; Wang R; Ji T; Tang X; Guo W
    Transl Pediatr; 2023 Mar; 12(3):470-486. PubMed ID: 37035391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up in osteogenesis imperfecta type VI.
    Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
    Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Osteogenesis Imperfecta.
    Ralston SH; Gaston MS
    Front Endocrinol (Lausanne); 2019; 10():924. PubMed ID: 32117044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial.
    Hoyer-Kuhn H; Franklin J; Allo G; Kron M; Netzer C; Eysel P; Hero B; Schoenau E; Semler O
    J Musculoskelet Neuronal Interact; 2016 Mar; 16(1):24-32. PubMed ID: 26944820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and Developing Pharmacologic Agents for Improving Skeletal Health in Adults with Osteogenesis Imperfecta.
    Liu W; Nicol L; Orwoll E
    Calcif Tissue Int; 2024 Mar; ():. PubMed ID: 38472351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α.
    Brunetti G; Papadia F; Tummolo A; Fischetto R; Nicastro F; Piacente L; Ventura A; Mori G; Oranger A; Gigante I; Colucci S; Ciccarelli M; Grano M; Cavallo L; Delvecchio M; Faienza MF
    Osteoporos Int; 2016 Jul; 27(7):2355-2365. PubMed ID: 26856585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic Antiresorptive: Denosumab.
    Kumar L; Arora MK; Marwah S
    Indian J Orthop; 2023 Dec; 57(Suppl 1):127-134. PubMed ID: 38107799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
    Varenna M; Gatti D
    Reumatismo; 2010; 62(3):163-71. PubMed ID: 21052563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do femoral fractures in adult patients with osteogenesis imperfecta imitate atypical femoral fractures? A case series.
    Andersen JD; Bünger MH; Rahbek O; Hald JD; Harsløf T; Langdahl BL
    Osteoporos Int; 2019 Feb; 30(2):513-517. PubMed ID: 30448959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
    Boskey AL; Marino J; Spevak L; Pleshko N; Doty S; Carter EM; Raggio CL
    Clin Orthop Relat Res; 2015 Aug; 473(8):2587-98. PubMed ID: 25903941
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.